P rostate cancer represents the most frequent non-cutaneous neoplasia in males. This type of neoplasia can develop peculiar patterns of evolution, presenting, in many cases, precocious relapses and metastasis. Bone metastasis in the mouth is extremely rare, and represents 1% of all malignant mouth neoplasias. The aim of the present study is to report a clinical case of bone metastasis in the mandibular region associated with a tumoral prostate adenocarcinoma, as well as to discuss connected aspects about diagnosis, prognosis and integrated treatment of this condition.
INTRODUCTION
Prostate cancer represents the most frequent non-cutaneous neoplasia in males, corresponding to 40% of the cases, being the second death cause due to malignant tumors in men. The incidence as much as the mortality increases exponentially after 50 years of age 5, 9, 10 . This type of neoplasia can develop peculiar patterns of evolution, presenting, in many cases, precocious relapse and metastasis. Of a total of patients who have received curative treatment for the localized prostate cancer, 30% relapse. The most frequent is the bone metastasis, generally multiple, mainly reaching the vertebral column, shoulder joints and sacroiliac bone. Among these patients, survival generally varies from 20 to 30 months 5, 10 . Bone metastasis in the mouth is extremely rare, and represents 1% of all malignant mouth neoplasias. The incidence is 80 to 90% in the mandible, mainly in the molar region and it always sign the spreading of the cancer illness. It originates from primary malignant neoplasias located mainly in the breast, prostate, lung, thyroid and kidney. However, the occurrence of prostate and kidneys as primary fields for jaw's metastasis through blood pathways are considered extremely rare 1, 16 . Among the bone metastases affecting the oral cavity, adenocarcinoma is the most frequent histological type 1, 16, 23 . Figure 1 ).
Through a radiography exam, it was possible to define a mild, diffuse radiolucency in the left mandibular body. The Computed Tomography Scan showed an anatomical structure alteration with osteolysis areas in the premolars, molars and in the left region of the chin (Figures 2 and 3) .
Because of that, we carried out an incisional biopsy and culture/antibiogram of sensitivity of the affected area. The results showed adenocarcinoma (clear cell type) with necrosis areas and infiltrating bone and soft tissue. The isolated microorganism was Staphylococcus aureus. These findings suggest was admitted to the Clinical Oncology Department with a metastatic bone disease diagnosis (prostate acinar adenocarcinoma) confirmed by three different methods: bone scintigraphy, incisional biopsy and immunohistochemical analysis of mandibular lesions. The treatment consisted of the use of goserelin acetate (3.6 mg/month) and bisphosphonate (clodronate, 4 ampoules/month). The patient was evaluated as having good disease control and good tolerance to treatment for some months, when disseminated neoplasm and pulmonary involvement led to a lethal outcome, with the patient's death in less than a year.
DISCUSSION
The PSA is a kallikrein family protease, produced by the prostate epithelium, whose function is to solubilize the sperm after ejaculation. The accepted level as the upper limit of normal PSA is 4 ng/ml 18 . The PSA has a great clinical utility; it serves for early detection of prostate cancer, cancer staging, prognostic assessment and therapeutical response control 3 . In addition to the PSA level in case of established disease, it is necessary to evaluate the prostate cancer advancement by image exams [transrectal ultrasound, bone scintigraphy, chest radiography, computed tomography of the abdomen and pelvis, magnetic nuclear resonance of the abdomen and pelvis, and positron emission tomography (PeT)] to define the appropriate therapeutical strategy. In order to classify neoplastic levels, some methods are used to analyze the histological grade (Gleason score), tumor volume and stage at the diagnosis time [12] [13] [14] 16 . When the primary tumor volume is less than 3 ml, metastasis rarely occurs. When the present volume is greater than 12 ml metastasis is almost always present 5, 16 . According to McNeal 11 (1992), only tumors larger than 1 cm in diameter (volume of 0.5 ml) are capable of extracapsular extension. The lymph nodes or seminal vesicles spread are usually more common in tumors larger than 2 cm in diameter 11 . The Gleason system has been introduced to aid on the tumor evolution prediction and the pathological staging by transrectal biopsy or of the surgical specimen itself. The lesions with Gleason score 2-4 (well differentiated) have a more indolent behavior, whereas the ones scoring 7-10 (undifferentiated) are aggressive, responding poorly to various treatment options 6 . The clinical staging of tumors, TNM classification, has been adopted to characterize tumors, helping in choosing the most appropriate therapy and to estimating the patients' survival chances. This system evaluates the primary tumor, regional lymph nodes and distant metastases 19 . The patients' selection for specific treatments is usually done through the risk of tumor recurrence and dissemination subdivision. Among the therapeutical modalities there are clinical observation, surgery, radiotherapy, chemotherapy, hormonal therapy and combination therapy.
Rutsatz, et al. 17 (1990) in a period of 35 years, reported 1008 patients with craniofacial malignancies, found only five patients (0.5%) with metastatic tumors to the jaw, from different primary sites. Van der Waal, et al.
23 (2003), identified adenocarcinoma as the primary histological type responsible for gnathic bone metastases, starting from different locations of primary tumors, confirming the reported case.
The four most common tumor sites that metastasize to the man jaws, in descending order of frequency, are lung, prostate, kidney and liver and, in women, breast, adrenal gland, female genital organs (uterus, cervix, ovaries) and colorectum. In the first decade of life, tumors of the adrenal gland (neuroblastoma) most frequently spread to the jaws and in the second decade, bone primaries prevail (osteosarcoma, ewing's/PNeT) 8 . Most patients with oral metastasis, generally have the primary cancer well diagnosed, confirming the reported case in which the primary tumor was treated years before by radical prostatectomy and the patient was still on medical care during the gnathic metastasis. In 25-35% of cases, the presence of metastasis on the head and neck is the first sign of disseminated malignant disease, and in about 70% of cases, metastatic lesions are diagnosed in conjunction with the primary focus. Sometimes, however, the diagnosis of the primary lesion may be difficult or even impossible 2, 21 . Multidisciplinary work is recommended in the care of patients with malignant neoplasms or neurological disorder of doubtful identification in order to provide diagnosis, planning and treatment that offer the most favorable prognosis.
Piattelli, et al. 15 (1999) conducted a survey of 390 oral cancer cases, of which 22 cases (5.6%) were metastatic tumors on gnathic bones from other regions, being prostate gland the primary site of these tumors, as occurred in our case.
In cases of metastatic bone illness, the pain and pathological fractures are prevalent manifestations, although the condition is asymptomatic in some patients. In this case, the patient reported the presence of chronic pain in hemi mandible, including a localized paresthesia, symptoms that were initially treated as Trigeminal Neuralgia. However, by conducting special examinations, we obtained the diagnosis of metastatic adenocarcinoma prostate cancer in the lung and bone, involving, in addition to the cited organs, the mandibular region. Bone tumor involvement of the oral region is higher compared to the soft tissue. Metastatic disease in the jaws may also affect the adjacent soft tissues and present as dental or periodontal infection 20 . When the metastasis is located in the jaw, the primary neoplasm is more likely to develop bone metastases, especially in the molar region 1 . It is believed that the greatest amount of cancellous bone present in the region is the reason for the higher frequency of involvement when compared to other facial bones, as trabecular bone presents growth factors that improve the neoplasia spread, confirming the reported case in which bone metastasis reached the region of the body and the mandibular symphysis 8 . The unilateral paresthesia type, as occurred in this case, hypoesthesia or anesthesia of the lower lip, known as Numb Chin Syndrome with or without the presence of pain, may be the initial clinical manifestation of a significant percentage that manifests on the jaw. Alterations in sensitivity involving the lower lip, even without significant radiological changes, should alert the expert to think about the possibility of an initial metastasis 1, 21 . For an accurate diagnosis and treatment of this rare condition, detailed and careful evaluation of the clinical picture, associated with a high degree of suspicion, is needed, requiring a multidisciplinary approach to the case 8, 21 . The prognosis of these patients is reserved for the pathophysiology of the primary tumor. Usually, with minimal cellular differentiation they may render the initial site location. In addition, bone metastases are associated with advanced disease and in some cases may be involved in malignant lesions -which may lead the patient to death, as reported in this case 7 . The radiation treatment can be considered curative regarding single oral metastases whose primary focus is clearly identified and which responded well to therapy. However, most authors consider an unfavorable prognosis for most cases of this oral cancer 2 . Surgical treatment in most cases is not recommended, indicating palliative therapy. The cases that may have a better indication are those with localized metastases, with no other identified metastasis and controlled primary disease, which does not occur in our case, since the examination of bone scintigraphy identified multiple metastatic tumors distributed throughout the body, palliative therapy being considered the best alternative 14 .
Chemotherapy is indicated only in metastatic disease refractory to hormonal treatment, as in cases of predominance of hormone-independent cell clones or progressive increase in serum PSA 22 . The use of bisphosphonates, as reported in the present case, is justified in the presence of bone metastases and when refractory to hormonal treatment, despite the risk of complications related to these drugs, such as osteonecrosis. There is an interesting indication to the use of these drugs as this therapy provides control of the neoplastic disease and also a relative patient survival chance 4 . In advanced cases, the quality of life, despite the patients having no chance of cure for the disease, is the main objective, providing less pain and discomfort 17 .
FINAL CONSIDERATIONS
Metastatic lesions are related to the advanced stage of the disease and usually with a high degree of histological aggressiveness. This fact explains the difficulty of curative treatment, and these injuries are usually classified as reserved and dark prognosis. It is important to emphasize the relevance of detailed clinical examination and multidisciplinary evaluation in order to establish the differential diagnosis and so the correct treatment.
